Does interruption of imatinib (IM) in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival

10556 Background: IM must not be interrupted after one year (yr) in responding patients (pts) (JCO 2007). The impact of IM re-introduction at progression (PD) remains unknown on the duration of GIS...